{
  "ticker": "OIL",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02963671",
  "id": "02963671",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250630",
  "time": "1325",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250630/pdf/06l89lzs5ls776.pdf",
  "summary": "- **Clinical Study Initiation**: Optiscan begins first-in-human breast cancer study at Royal Melbourne Hospital using InVue\u00ae (in vivo imaging) and InForm\u2122 (ex vivo imaging) devices.  \n- **Regulatory Pathway**: Study data will support US FDA submissions for both devices.  \n- **Patient Recruitment**: 50 patients undergoing breast-conserving surgery will be enrolled.  \n- **Key Potential Impact**: Successful outcomes could demonstrate real-time tumor margin assessment, reducing need for follow-up surgeries and advancing precision oncology.  \n\n*No capital markets or trading-specific material information identified (e.g., no funding, timelines, or financial metrics provided).*",
  "usage": {
    "prompt_tokens": 2671,
    "completion_tokens": 134,
    "total_tokens": 2805,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-30T04:05:56.940817"
}